Technical Analysis for POAI - Predictive Oncology Inc.

Grade Last Price % Change Price Change
grade F 0.594 -7.59% -0.05
POAI closed down 7.59 percent on Wednesday, August 21, 2019, on 1.46 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical POAI trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Inside Day Range Contraction 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -7.59%
Crossed Above 20 DMA Bullish -7.59%
Pocket Pivot Bullish Swing Setup -7.59%
Earnings Movers Other -7.59%
Outside Day Range Expansion -7.59%
Up 3 Days in a Row Strength -7.59%

Older signals for POAI ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Predictive Oncology (formerly Precision Therapeutics Inc.) (Nasdaq: AIPT until June 12, 2019; POAI starting June 13, 2019) operates through its three business units, Helomics, TumorGenesis and Skyline Medical. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy. In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor™, patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform (D-CHIP) to provide a tailored solution to its clients’ specific needs. Predictive Oncology’s TumorGenesis subsidiary is developing a new rapid approach to growing tumors in the laboratory, which essentially “fools” cancer cells into thinking they are still growing inside a patient. Its proprietary Oncology Discovery Technology Platform kits will assist researchers and clinicians to identify which cancer cells bind to specific biomarkers. Once the biomarkers are identified they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and help categorize an individual patient’s heterogeneous tumor samples to enable the development of patient specific treatment options. Helomics and TumorGenesis are focused on ovarian cancer. Predictive Oncology’s Skyline Medical division markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners.
Medicine Biotechnology Cancer Pharmaceutical Clinical Medicine Oncology Artificial Intelligence Ovarian Cancer Cell Biology Tumors Genomics FDA Targeted Therapy Cancer Therapies Bioinformatics Biomarkers Proteomics Precision Medicine
Is POAI a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 1.24
52 Week Low 0.4
Average Volume 70,302
200-Day Moving Average 0.7477
50-Day Moving Average 0.6513
20-Day Moving Average 0.626
10-Day Moving Average 0.6037
Average True Range 0.0621
ADX 21.24
+DI 13.7625
-DI 16.4805
Chandelier Exit (Long, 3 ATRs ) 0.5277
Chandelier Exit (Short, 3 ATRs ) 0.7363
Upper Bollinger Band 0.6888
Lower Bollinger Band 0.5632
Percent B (%b) 0.25
BandWidth 20.063898
MACD Line -0.018
MACD Signal Line -0.0167
MACD Histogram -0.0013
Fundamentals Value
Market Cap 3.7 Million
Num Shares 6.23 Million
EPS -1.11
Price-to-Earnings (P/E) Ratio -0.53
Price-to-Sales 21.74
Price-to-Book 3.75
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.71
Resistance 3 (R3) 0.71 0.67 0.69
Resistance 2 (R2) 0.67 0.64 0.67 0.69
Resistance 1 (R1) 0.63 0.62 0.61 0.63 0.68
Pivot Point 0.59 0.59 0.58 0.59 0.59
Support 1 (S1) 0.55 0.56 0.53 0.55 0.51
Support 2 (S2) 0.51 0.54 0.51 0.50
Support 3 (S3) 0.47 0.51 0.49
Support 4 (S4) 0.47